Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Investor Presentation (September 2023)
9 slides from Sanara Medtech's investor presentation, Sep 19, 2023
Slide 1: Sanara MedTech Overview
Sanara MedTech Overview September 2023 Sanara MedTech Evidence Based Healing
Slide 2: Disclaimers
Disclaimers MedTech ‘This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the "Company," "Sanara," ‘we,” “our” or “us"). All statem
Slide 3: Overview: Product Offering and Opportunity
Sanara MedTech Overview Product Offering and Opportunity Key Differentiators Driving Future Growth Sanara MedTech $60 million 63% Growth Q2 TTM Revenue Q2 2023/Q2 2022 Highly Accomplished Sales Team 33 States !(50 Planned) | Multiple Product Selling Opportunities Per Case Growing Distribution Capabi
Slide 4: Overview (cont'd.)
Sanara MedTech Overview (cont’d.) Portfolio Built to Compliment Surgical Outcomes & Reduce Post-Operative Cost of Care «€) Sanara MedTech ° Soft Tissue . CellerateRX® Surgical FORTIFY TRG® Tissue FORTIFY TEXAGEN® Amniotic Membrane Activated Collagen Repair Graft FLOWABLE® ECM Allograft Type 1 Porcin
Slide 5: Large Untapped Addressable Market
Large Untapped Addressable Market Multibillion Dollar Market Opportunity with Demographic Tailwinds Sanara MedTech Conditions Driving Future Product Adoption Currently developing a $ Current ‘ au sed carte naresable ft. jing Population U.S. Wound Care market 7.3BN U.S. Market Growing prevalence of h
Slide 6: Building a Leading Medical Technology Company
Sanara MedTech Building a Leading Medical Technology Company Management Has Developed and Executed a Multi-year Growth Strategy + Rochal asset acquisition (brought R&D in-house) + Launched Cook Biotech Inc. products (expanded product offering) Constructing a leading wound care and biologics platform
Slide 7: Recent Developments & Key Updates
Recent Developments & Key Updates Product Launch, M&A, and GPO Contract to Drive Continued Performance Sanara MedTech BIASURGE 510(k) Clearance and Expected Commercial Launch in Q4’23 Acquisition of Assets Related to Collagen Products Business ined Major National GPO, which Added ~1,300 New Faci S I
Slide 8: Sanara Post-Acute Value-Based Care Strategy
clinical deliver 1*t value-based bundling of advanced products, wound care technology, and for $36B+ fragmented post acute market. Sanara Post-Acute Value-Based Care Strategy Reducing Hospital Spend and Improving Outcomes Products + Advanced dressings + Advanced wound biologics + Negative pressure p
Slide 9: Questions?
Questions? Sanara MedTech Evidence Based Healing
Sanara MedTech — Investor Presentation (September 2023) on 6ix